Family · cognitive
Pinealon
EDR peptide (Glu-Asp-Arg tripeptide)
A synthetic tripeptide (glutamate-aspartate-arginine) from Khavinson's short-peptide bioregulator group, proposed in preclinical work to influence gene expression and offer neuroprotection; the DNA-interaction mechanism remains hypothetical.
Preliminary evidence, mostly in vitro and small animal models from affiliated Russian laboratories, with little independent replication and no human clinical trials. Not an approved drug.
- Studied in cell and rodent models of neuroprotection
- Researched in Alzheimer's-model neuronal cultures
- Explored for circadian and antioxidant signalling
Educational overview only — no dosing instructions in the public hub.
Human safety is essentially uncharacterised due to the absence of clinical trials; sourcing/purity is the main practical risk.
Third-party CoA (purity + quantification + MS) is the minimum verification.
Research-use-only in most jurisdictions; not approved for human use by the FDA, EMA, or MHRA.
Frequently asked questions
- What is Pinealon used for?
- Studied in cell and rodent models of neuroprotection. Researched in Alzheimer's-model neuronal cultures. Explored for circadian and antioxidant signalling. Preliminary evidence, mostly in vitro and small animal models from affiliated Russian laboratories, with little independent replication and no human clinical trials. Not an approved drug.
- Is Pinealon legal in Europe?
- Research-use-only in most jurisdictions; not approved for human use by the FDA, EMA, or MHRA.
- What are the risks and side effects of Pinealon?
- Human safety is essentially uncharacterised due to the absence of clinical trials; sourcing/purity is the main practical risk.
- How is the quality of Pinealon assessed?
- Third-party CoA (purity + quantification + MS) is the minimum verification.